In December 2017, the US Food & Drug Administration (FDA) approved Luxturna from Spark Therapeutics — the first gene therapy to win market approval in the US. Several other gene therapy programs ...

If approved it would compete with Novartis’ Luxturna (voretigene neparvovec), the gene therapy from Roche/Spark Therapeutics, but with a much broader indication. Luxturna only works in people ...

The first NHS patients have started treatment with Novartis’ Luxturna, a gene therapy for a sight-robbing inherited disease, after the drugmaker agreed a discount on its £613,000 list price ...

Luxturna (voretigene neparvovec), has been ... under 90 people in England will be eligible for the treatment. The gene therapy is for patients who have retinal dystrophy as a result of inheriting ...

In 2019 the NHS agreed to fund the treatment, Luxturna, the first in a new generation ... About 100 people in the UK are likely to be eligible for the gene therapy, which is being carried out ...

This approach yields a reasonable output of fully-assembled, gene therapy-ready rAAV particles ... including Spark Therapeutics’ Luxturna and a pair of other therapies now in phase 3 testing ...

Aaron Nagiel treats the first patient at CHLA with Luxturna retinal gene therapy in 2017. In 2024, Dr. Nagiel's team celebrated its 100th Luxturna procedure. (Photo: Business Wire) There’s no ...

Dr. Aaron Nagiel discusses how CHLA is advancing sight-saving gene therapy treatments and treating more Luxturna patients than any other center in the country. His newly treated patients might ...

You have permission to edit this article. Edit Close Newsletter Facebook Instagram ...

(Photo: Business Wire) Dr. Aaron Nagiel discusses how CHLA is advancing sight-saving gene therapy treatments and treating more Luxturna patients than any other center in the country. There’s no ...